CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 159 enrolled
Drug / intervention
MPC Intramyocardial Injection +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02362646
NCT02362646Phase 2Completed
CompareCT.gov

Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients

Annetine Gelijns·interventional·Posted Feb 13, 2015·Updated Nov 26, 2019

In Brief

A Phase 2 clinical trial evaluating MPC Intramyocardial Injection and Control Solution for Heart Failure and 2 related conditions. Completed, enrolled 159 participants across 19 sites in 2 countries.

Detailed Summary

The main purpose of this research is to determine whether injecting mesenchymal precursor cells (MPC) into the heart during surgery to implant a left ventricular assist device (LVAD) is safe. MPCs are normally present in human bone marrow and have been shown to increase the development of blood vessels and new heart muscle cells in the heart. In addition, this research is being done to test whether injecting the MPCs into the heart is effective in improving heart function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Cardiomyopathy, Ventricular Dysfunction
CountriesCanada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 13, 2015
Enrollment StartJul 1, 2015
Primary CompletionAug 10, 2018
Study CompletionAug 23, 2019
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.4 years ago

Interventions

MPC Intramyocardial Injectionbiological

Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation

Control Solutiondrug